Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Block of Human CaV3 Channels by the Diuretic Amiloride

Osbaldo Lopez-Charcas, Manuel Rivera and Juan C. Gomora
Molecular Pharmacology October 2012, 82 (4) 658-667; DOI: https://doi.org/10.1124/mol.112.078923
Osbaldo Lopez-Charcas
Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México, Distrito Federal, México
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Rivera
Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México, Distrito Federal, México
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan C. Gomora
Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México, Distrito Federal, México
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previous studies in native T-type currents have suggested the existence of distinct isoforms with dissimilar pharmacology. Amiloride was the first organic blocker to selectively block the native T-type calcium channel, but the potency and mechanism of block of this drug on the three recombinant T-type calcium channels (CaV3.1, CaV3.2, and CaV3.3) have not been systematically determined. The aim of the present study was to investigate whether there is differential block of CaV3 channels by amiloride, to establish the mechanism of block, and to obtain insights into the amiloride putative binding sites in CaV3 channels. By performing whole-cell patch-clamp recordings of human embryonic kidney 293 cells stably expressing human CaV3 channels, we found that amiloride blocked the human CaV3 channels in a concentration-response manner; the IC50 for CaV3.2 channels (62 μM) was 13-fold lower than that for CaV3.1 and CaV3.3. Block is voltage-independent (except for CaV3.3 channels) and targets mainly closed-state channels, although a small use-dependent component was observed in CaV3.1 channels. In addition, amiloride block of CaV3.2 channels is mainly due to an extracellular effect, whereas in CaV3.1 and CaV3.3 channels, the amiloride inhibition is equally effective from both sides of the membrane. The results demonstrate that amiloride blocks human CaV3 channels differentially through a mechanism involving mainly the closed state of the channel and suggest a negative allosteric interaction with at least two putative binding sites with different affinities. The preferential block of CaV3.2 channels labels amiloride as the only organic blocker to be selective for any T-type channel.

Footnotes

  • This work was supported by the Consejo Nacional de Ciencia y Tecnología [Grant J50250Q] and the Instituto de Ciencia y Tecnología del Distrito Federal [Grant PICDS08−28] (to M.R.).

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.112.078923.

  • ABBREVIATIONS:

    CaV
    voltage-gated calcium
    LVA
    low-voltage-activated
    HVA
    high-voltage-activated
    HP
    holding potential
    HEK
    human embryonic kidney
    AMI
    amiloride.

  • Received March 24, 2012.
  • Accepted July 5, 2012.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 82 (4)
Molecular Pharmacology
Vol. 82, Issue 4
1 Oct 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Block of Human CaV3 Channels by the Diuretic Amiloride
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Amiloride Block of CaV3 Channels

Osbaldo Lopez-Charcas, Manuel Rivera and Juan C. Gomora
Molecular Pharmacology October 1, 2012, 82 (4) 658-667; DOI: https://doi.org/10.1124/mol.112.078923

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Amiloride Block of CaV3 Channels

Osbaldo Lopez-Charcas, Manuel Rivera and Juan C. Gomora
Molecular Pharmacology October 1, 2012, 82 (4) 658-667; DOI: https://doi.org/10.1124/mol.112.078923
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Relapsed-Leukemia Model with NT5C2/PRPS1 Hotspot Mutations
  • The Binding Site for KCI807 in the Androgen Receptor
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics